Le 5 février/February 2021

	The common shares of Bright Minds Biosciences Inc. have been approved for listing on the CSE.

	Listing and disclosure documents will be available at&nbsp;<a href="https://thecse.com/en/listings/life-sciences/bright-minds-biosciences-inc">www.thecse.com</a>&nbsp;on the trading date.

	Bright Minds is a pre-clinical biosciences company with a portfolio of compounds designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. Bright Minds is focused on developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious neuropsychiatry drugs into the clinic. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin. Bright Minds was selected to participate in two National Institutes of Health (“NIH”) Programs. These NIH collaborations are evaluating Bright Minds serotonin agonists for therapeutic potential in pain and in epilepsy.

	________________________________

	Les actions ordinaires de Bright Minds Biosciences Inc. ont été approuvées pour inscription au CSE.

	Les documents d'inscription et de divulgation seront disponibles sur <a href="https://thecse.com/fr/inscriptions/sciences-biologiques/bright-minds-biosciences-inc">www.thecse.com</a> à la date de négociation.

	Bright Minds est une société de biosciences précliniques avec un portefeuille de composés conçus pour cibler précisément les anomalies dans les neurocircuits qui conduisent à des comportements dysfonctionnels. Bright Minds se concentre sur le développement de thérapies ciblées ayant le potentiel d'améliorer le traitement de la santé mentale et des troubles neurologiques grâce à l'utilisation de composés sérotoninergiques en tirant parti de son expertise de classe mondiale en matière de développement scientifique et de médicaments pour faire progresser la prochaine génération de médicaments neuropsychiatriques sûrs et efficaces dans le clinique. Les médicaments Bright Minds atténuent les aspects thérapeutiques des composés psychédéliques et autres sérotoninergiques tout en minimisant les effets secondaires, créant ainsi des médicaments supérieurs aux composés de première génération, tels que la psilocybine. Bright Minds a été sélectionné pour participer à deux programmes des National Institutes of Health («NIH»). Ces collaborations des NIH évaluent les agonistes de la sérotonine de Bright Minds pour leur potentiel thérapeutique dans la douleur et l'épilepsie.
<table border="1" cellpadding="1" cellspacing="1" >
<tbody>
<tr>
<td >
				Issuer/Émetteur:</td>
<td >
				Bright Minds Biosciences Inc.</td>
</tr>
<tr>
<td>
				Security Type/Titre:</td>
<td>
				Common&nbsp;Shares/Actions&nbsp;ordinaires</td>
</tr>
<tr>
<td>
				Symbol(s)/Symbole(s):</td>
<td>
				DRUG</td>
</tr>
<tr>
<td>
				Number of securities issued and outstanding/&nbsp;Titres&nbsp;émis&nbsp;et en circulation:</td>
<td>
				6 403 478</td>
</tr>
<tr>
<td>
				Number of Securities reserved for issuance/&nbsp;Titres&nbsp;réservés&nbsp;pour&nbsp;émission:</td>
<td>
				5 056 600</td>
</tr>
<tr>
<td>
				CSE Sector/Catégorie:</td>
<td>
				Life Sciences/Sciences biologiques</td>
</tr>
<tr>
<td>
				CUSIP:</td>
<td>
				10919W 10 8</td>
</tr>
<tr>
<td>
				ISIN:</td>
<td>
				CA 10919W 10 8 6</td>
</tr>
<tr>
<td>
				Boardlot/Quotité:</td>
<td>
				100</td>
</tr>
<tr>
<td>
				Trading&nbsp;Currency/Monnaie&nbsp;de&nbsp;négociation:</td>
<td>
				CDN$/$CDN</td>
</tr>
<tr>
<td>
				Trading Date/Date de&nbsp;negociation:</td>
<td>
				le 8 février/February 2021</td>
</tr>
<tr>
<td>
				Other Exchanges/Autres&nbsp;marches:</td>
<td>
				N/A</td>
</tr>
<tr>
<td>
				Fiscal Year&nbsp;end /Clôture&nbsp;de&nbsp;l'exercice&nbsp;financier:</td>
<td>
				le 30 septembre/September</td>
</tr>
<tr>
<td>
				Transfer Agent/Agent des&nbsp;transferts:</td>
<td>
				Computershare Investor Services Inc.</td>
</tr>
</tbody>
</table>

	The Exchange is accepting Market Maker applications for DRUG. Please email:&nbsp;<a href="mailto:Trading@theCSE.com">Trading@theCSE.com</a>

	If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail:&nbsp;<a href="mailto:Listings@thecse.com">Listings@thecse.com</a>

	Pour toute question, pour obtenir de l’information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l’adresse:&nbsp;&nbsp;<a href="mailto:Listings@thecse.com">Listings@thecse.com</a>

Bright Minds Biosciences Inc.

2021-0215 – New Listing - Bright Minds Biosciences Inc. (DRUG)

CSE25™

CSE Composite Index®

In this series, we delve deep into the experiences of CSE listed companies, exploring their past successes and future opportunities.

CSE Issuer Spotlight

**Follow us** for the **latest news** from the CSE

 The CSE provides a modern and efficient alternative for companies looking to access the Canadian public capital markets.

The Canadian Securities Exchange (CSE)

Learn how we streamline issuer regulation through enhanced disclosure, practical and effective regulatory oversight, and modern technology.

Listing on the CSE

Learn more about the companies we list and how to get started trading on the CSE.

Investing in Listed Companies

Learn how we lower costs, reduce complexity, and provide market making opportunities for the dealer community.

Trading on the CSE

Whether you’re an investor, business leader, or simply looking to learn more, start your journey with the CSE here.

Get Started

From announcements and market updates to in-depth interviews with company leaders - stay informed with the latest from the CSE.

Latest from the CSE

Discover newly listed companies on the CSE through our series of bite-sized interviews with company leaders.

Get to know our latest listings

Listed Company News

Market Activity

List with the CSE

Find a home for your next big idea.

Frequently Asked Questions

How does being listed on the CSE affect me as a shareholder?

Where do I get information and trade CSE listed securities?

Where can I find an RSS feed for listed company news?

Where is the CSE recognized?

Upcoming Events

join the list

Join our mailing list to receive buy-in notifications

The CSE provides a superior exchange experience by investing in our customers’ success with innovation, dedication, and passion.

Where innovation, passion, and trust intersect

We strive to be the most innovative exchange in Canada. We aim to offer unlimited global access and a customized client-centric experience while delivering the lowest cost of public capital. 

We are Canada's entrepreneurial exchange

The most searched CSE listed companies on thecse.com

Recent Quotes

Get the latest regulatory announcements from the CSE concerning its Listings Policies, Trading Rules and functionality and other important industry developments.

Notices

Get the latest information about new CSE listings, the appointment of Market Makers, market events, and other news.

Bulletins

Stay informed with CSE listed company news, providing transparency and accountability to shareholders and the public.

Company News

Stay Informed

The **total volume** traded on the CSE today is

Connect with our professionals and listing experts at industry events and conferences.